Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 3/20 | 0.46 |
| ▸ | CES1 | P23141 | 3/20 | 0.46 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.45 |
| ▸ | PPARG | P37231 | 7/20 | 0.45 |
| ▸ | PPARD | Q03181 | 7/20 | 0.45 |
| ▸ | PPARA | Q07869 | 7/20 | 0.45 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.45 |
| ▸ | TSHR | P16473 | 4/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | TLR2 | O60603 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | FABP4 | P15090 | 2/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.45 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.45 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL540003 | 0.86 | CES2 (0.48) | CES2CES1GPR84PPARGPPARD | |
| Hydrochloric Acid SCHEMBL2125074 | 0.84 | CES2 (0.46) | CES2CES1GPR84PPARGPPARD | |
| SCHEMBL27333657 | 0.80 | CNR1 (0.54) | MAPTMAPK1CES2CES1GPR84 | |
| SCHEMBL28530660 | 0.79 | GPR84 (0.45) | MAPTMAPK1CES2CES1GPR84 | |
| SCHEMBL2235149 | 0.79 | GPR84 (0.45) | MAPTMAPK1CES2CES1GPR84 | |
| SCHEMBL28626297 | 0.79 | DNM1 (0.45) | CES2CES1GPR84PPARGPPARD | |
| SCHEMBL825632 | 0.79 | GPR84 (0.45) | MAPTMAPK1CES2CES1GPR84 | |
| SCHEMBL2235152 | 0.79 | GPR84 (0.45) | MAPTMAPK1CES2CES1GPR84 | |
| SCHEMBL28530662 | 0.79 | GPR84 (0.45) | MAPTMAPK1CES2CES1GPR84 | |
| SCHEMBL825631 | 0.79 | GPR84 (0.45) | MAPTMAPK1CES2CES1GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1900364-B1 | Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors | PROMETIC BIOSCIENCES INC (CA) | 2013-09-25 | — | — | EP | disclosed |
| US-8487001-B2 | Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors | PROMETIC BIOSCIENCES INC. (CA) | 2013-07-16 | — | — | US | disclosed |
| US-20100279959-A1 | Medium-Chain Length Fatty Acids, Glycerides and Analogues as Neutrophil Survival and Activation Factors | PROMETIC PHARMA SMT LIMITED (GB) | 2010-11-04 | — | — | US | disclosed |
| US-7745488-B2 | Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors | PROMETIC BIOSCIENCES, INC. (CA) | 2010-06-29 | — | — | US | disclosed |
| EP-1900364-A2 | MEDIUM-CHAIN LENGTH FATTY ACIDS, GLYCERIDES AND ANALOGUES AS NEUTROPHIL SURVIVAL AND ACTIVATION FACTORS | ProMetic BioSciences Inc. (CA) | 2008-03-19 | — | — | EP | disclosed |
| US-20040147599-A1 | Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors | PROMETIC PHARMA SMT LIMITED (GB) | 2004-07-29 | — | — | US | disclosed |
| EP-1385498-A2 | MEDIUM-CHAIN LENGTH FATTY ACIDS, GLYCERIDES AND ANALOGUES AS NEUTROPHIL SURVIVAL AND ACTIVATION FACTORS | Prometic Biosciences Inc. (CA) | 2004-02-04 | — | — | EP | disclosed |
| WO-2002083120-A2 | MEDIUM-CHAIN LENGTH FATTY ACIDS, GLYCERIDES AND ANALOGUES AS NEUTROPHIL SURVIVAL AND ACTIVATION FACTORS | PROMETIC BIOSCIENCES INC. (CA) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147599-A1 | Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors | MYD88, CSF3R, MCTS1 | MAPT 2371/4885MAPK1 1116/4885CES2 920/4885 |
| US-20100279959-A1 | Medium-Chain Length Fatty Acids, Glycerides and Analogues as Neutrophil Survival and Activation Factors | MYD88, CSF3R, MCTS1 | MAPT 2371/4885MAPK1 1116/4885CES2 920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.